CORONA Remedies Limited — Q3 FY26
Corona Remedies delivered a strong Q3 FY26 with revenue of ₹342 crore (+15% YoY), EBITDA of ₹83 crore (+20% YoY), and adjusted PAT of ₹56 crore (+24% YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
R&D spend to remain below 2% of revenue
R&D expenditure will stay below 2% of revenue as the company scales, with ~100 scientists currently; no major increase planned.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1